
OptiNose Investor Relations Material
Latest events

Q3 2024
OptiNose
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from OptiNose Inc
Access all reports
OptiNose Inc. is a pharmaceutical company engaged in the development and commercialization of innovative products for patients under the care of ear, nose, throat, and allergy specialists in the United States. The company has developed a proprietary Exhalation Delivery Systems, a novel drug delivery concept that facilitates broad, consistent drug delivery deep within the nasal passages. This technology aims to leverage the mucosal surfaces as a potential target for treating both local and systemic diseases. OptiNose's portfolio includes XHANCE, a therapeutic product utilizing EDS to deliver a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. Additionally, the company has developed Onzetra Xsail, a powder EDS device, and is exploring further applications of its technology in various clinical trials. OptiNose is headquartered in Yardley, Pennsylvania, and its shares are listed on the NASDAQ.
Key slides for OptiNose Inc


Q2 2024
OptiNose Inc


Q4 2023
OptiNose Inc
Latest articles
)
Robert G. Hagstrom: Darwinian Investing and Multidisciplinary Wisdom
Robert G. Hagstrom, author of The Warren Buffett Way, explores how interdisciplinary thinking shapes his investing, from Adler's reading to Darwinian markets.
7 Feb 2025
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
Ticker symbol
OPTN
Country
🇺🇸 United States